Everything ALS Video Presentation: “The Amydis Eye Test to Detect ALS”

Inside Amydis Strategy to Transform Neurodegenerative Disease Detection

March 30, 2026

Amydis awarded $2.5M to develop diagnostic eye test for ALS

March 16, 2026

Amydis receives phase 2 NIH grant award of $2.5 million to advance a novel approach to detect biomarker TDP-43

March 13, 2026

Amydis Receives Phase 2 NIH Grant Award to Advance a Novel Approach to Detect Biomarker TDP-43

March 13, 2026

Amydis lands NIA funding to detect ALS in the eye

March 11, 2026

NIH Awards $2.5 Million to Advance Eye-Based Detection of ALS Biomarker TDP-43

March 11, 2026

Seeing ALS Through the Eye: Amydis Receives Phase 2 NIH Grant Award to Advance a Novel Approach to Detect Biomarker TDP-43

March 11, 2026

Turning Sight into Insight: How Amydis Is Using the Retina to Rethink ALS Screening and Diagnostics 

May 15, 2025

Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference

October 10, 2024

Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer

February 18, 2024

Ex-NFL Star Gary Plummer Supports Amydis Mission: “This is a Game Changer”

January 26, 2024

Amydis Nabs $3.4M NIH Grant to Develop Retinal Biomarkers for Alzheimer’s

November 14, 2023

Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial

November 14, 2023

Amydis Unveils Phase 2 Clinical Trial for Glaucoma Detection Technology

November 8, 2023

Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta

November 2, 2023

Translational Research, Leading the Way to Early Detection and Life-Saving Diagnoses

September 1, 2023

Everything ALS Video Presentation: “The Amydis Eye Test to Detect ALS”

March 22, 2023

Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial

February 21, 2023

Advances in Retinal Biomarkers and Retinal Tracers

January 1, 2023

Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study Of A Retinal Tracer For Parkinson’s Disease

October 27, 2022

Amydis Receives NIH Grant Award to Develop a Novel TDP43 Retinal Tracer in Patients with ALS and FTD

August 19, 2022

Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board

March 29, 2022

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies

December 6, 2021

Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy

October 11, 2021

Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and other Tauopathies

September 2, 2021

Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy

June 28, 2021

Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS

April 26, 2021

Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye

August 11, 2020

Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy

September 23, 2019

Amydis Awarded Prion Disease Grant from NIH

September 26, 2018

Amydis Receives Parkinson’s Disease Grant from Michael J. Fox Foundation

July 10, 2018

NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics

October 9, 2017

Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease

March 19, 2017

Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer’s Disease

September 29, 2015